Peter S Maclean

Summary

Country: UK

Hereditary and acquired antithrombin deficiency: epidemiology, pathogenesis and treatment options
Peter S Maclean
Department of Haematology, Glasgow Royal Infirmary, Glasgow, UK
Drugs 67:1429-40. 2007
Ideal body weight correlates better with engraftment after PBSC autograft than actual body weight, but is under-estimated in myeloma patients possibly due to disease-related height loss
P S MacLean
Department of Clinical Apheresis, Scottish National Blood Transfusion Service, Glasgow Royal Infirmary, Scotland, UK
Bone Marrow Transplant 40:665-9. 2007
Treatment related factors and inhibitor development in children with severe haemophilia A
P S MacLean
Haemophilia Centre, Yorkhill Children s Hospital, Glasgow, UK
Haemophilia 17:282-7. 2011

Hereditary and acquired antithrombin deficiency: epidemiology, pathogenesis and treatment options
Peter S Maclean
Department of Haematology, Glasgow Royal Infirmary, Glasgow, UK
Drugs 67:1429-40. 2007
..A recombinant antithrombin product now under investigation, and recently licensed in Europe, may provide a useful alternative treatment option...
Ideal body weight correlates better with engraftment after PBSC autograft than actual body weight, but is under-estimated in myeloma patients possibly due to disease-related height loss
P S MacLean
Department of Clinical Apheresis, Scottish National Blood Transfusion Service, Glasgow Royal Infirmary, Scotland, UK
Bone Marrow Transplant 40:665-9. 2007
..We confirm that calculation of CD34+ cell dose by IBW safely predicts engraftment for patients with haematological malignancies other than myeloma undergoing PBSC autograft...
Treatment related factors and inhibitor development in children with severe haemophilia A
P S MacLean
Haemophilia Centre, Yorkhill Children s Hospital, Glasgow, UK
Haemophilia 17:282-7. 2011
..This study confirms treatment-related factors as important risks for inhibitor development in Haemophilia A...